140 related articles for article (PubMed ID: 14991863)
1. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Van Laar ES; Weitman S; MacDonald JR; Waters SJ
Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
[TBL] [Abstract][Full Text] [Related]
2. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
3. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
4. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
[TBL] [Abstract][Full Text] [Related]
5. Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo.
Van Laar ES; Roth S; Weitman S; MacDonald JR; Waters SJ
Anticancer Res; 2004; 24(1):59-65. PubMed ID: 15015576
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH
Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259
[TBL] [Abstract][Full Text] [Related]
8. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model.
Ahmed S; Johnson CS; Rueger RM; Trump DL
J Urol; 2002 Aug; 168(2):756-61. PubMed ID: 12131364
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Kelner MJ; McMorris TC; Rojas RJ; Trani NA; Estes L
Cancer Chemother Pharmacol; 2002 May; 49(5):412-8. PubMed ID: 11976836
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
[TBL] [Abstract][Full Text] [Related]
11. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
Dalrymple SL; Becker RE; Isaacs JT
Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
[TBL] [Abstract][Full Text] [Related]
12. Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer.
Pinto AC; Moreira JN; Simões S
Prostate; 2011 Jan; 71(1):81-90. PubMed ID: 20607721
[TBL] [Abstract][Full Text] [Related]
13. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
[TBL] [Abstract][Full Text] [Related]
15. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
[TBL] [Abstract][Full Text] [Related]
16. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
[TBL] [Abstract][Full Text] [Related]
17. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
Pinto AC; Moreira JN; Simões S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):445-54. PubMed ID: 19104815
[TBL] [Abstract][Full Text] [Related]
18. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
19. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
Yu DC; Chen Y; Dilley J; Li Y; Embry M; Zhang H; Nguyen N; Amin P; Oh J; Henderson DR
Cancer Res; 2001 Jan; 61(2):517-25. PubMed ID: 11212244
[TBL] [Abstract][Full Text] [Related]
20. A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.
Dahmani A; de Plater L; Guyader C; Fontaine JJ; Berniard A; Assayag F; Beuzeboc P; Marangoni E; Némati F; Poupon MF; Pasik C; Oudard S; Decaudin D
Anticancer Drugs; 2010 Nov; 21(10):927-31. PubMed ID: 20827173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
